15.63 USD
+0.58 (+3.85%)
15.63 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 78% to MCRB. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 21.42. This target is 37.04% above the current price.
- MCRB was analyzed by 9 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about MCRB.
- In the previous month the buy percentage consensus was at a similar level.
- MCRB was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-24 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-05-08 | Chardan Capital | Downgrade | Buy -> Neutral |
| 2025-03-20 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-14 | Goldman Sachs | Maintains | Sell -> Sell |
| 2024-11-14 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-11-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-10-24 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2024-09-13 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-08-14 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-08-14 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-06-07 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2024-06-07 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-05-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-05-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-03-06 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-03-06 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-01-16 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-11-03 | Goldman Sachs | Maintains | Sell -> Sell |
| 2023-04-28 | Chardan Capital | Maintains | Buy |
| 2023-04-21 | JP Morgan | Initiate | Neutral |
| 2023-03-21 | Canaccord Genuity | Maintains | Buy |
| 2023-03-08 | Chardan Capital | Reiterate | Buy |
| 2023-03-08 | Canaccord Genuity | Maintains | Buy |
| 2023-03-08 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-08 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-09-07 | Piper Sandler | Maintains | Overweight |
| 2022-05-23 | Piper Sandler | Maintains | Overweight |
| 2021-07-23 | Chardan Capital | Maintains | Buy |
| 2021-07-23 | Oppenheimer | Maintains | Outperform |
| 2021-07-23 | Canaccord Genuity | Maintains | Buy |
SERES THERAPEUTICS INC / MCRB FAQ
What is the price target for MCRB stock?
9 analysts have analysed MCRB and the average price target is 21.42 USD. This implies a price increase of 37.04% is expected in the next year compared to the current price of 15.63.
What is the consensus rating for MCRB stock?
The consensus rating for SERES THERAPEUTICS INC (MCRB) is 77.7778 / 100 . This indicates that analysts generally have a positive outlook on the stock.